Raymond James Financial’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$138M Sell
262,791
-10,164
-4% -$5.7M 0.04% 433
2026
Q1
$153M Buy
272,955
+16,603
+6% +$10.6M 0.05% 362
2025
Q4
$174M Sell
256,352
-16,239
-6% -$11.1M 0.05% 306
2025
Q3
$174M Buy
272,591
+61,818
+29% +$37.5M 0.06% 303
2025
Q2
$113M Buy
210,773
+17,517
+9% +$8.38M 0.04% 438
2025
Q1
$81.2M Buy
193,256
+19,366
+11% +$8.41M 0.03% 503
2024
Q4
$71.9M Buy
+173,890
New +$76.3M 0.03% 546

Other funds holding IDXX

Raymond James Financial's IDXX Position: Q2 2026 in Review

Raymond James Financial reduced its Idexx Laboratories (IDXX) stake by 3.7% in Q2 2026, selling an estimated $5.7M and leaving 262,791 shares worth $138M. The position accounts for 0.04% of the portfolio, ranked #433.

Raymond James Financial first reported a position in IDXX in Q4 2024 and has held it in 7 quarters since. The position peaked at $174M in Q4 2025. 1,306 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Raymond James Financial held 262,791 shares of Idexx Laboratories worth $138M as of Q2 2026.
  • Raymond James Financial sold 10,164 Idexx Laboratories shares in Q2 2026, an estimated $5.7M.
  • Idexx Laboratories made up 0.04% of Raymond James Financial's portfolio in Q2 2026, its #433 holding.
  • Raymond James Financial first reported a position in Idexx Laboratories in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Idexx Laboratories position peaked at $174M in Q4 2025.
  • 1,306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.